yes thats the question. Im trying to find the blue skyit appears...

yes thats the question. Im trying to find the blue sky
it appears the TAVR markets are massive and growing but any products from this company would at LEAST be 5-10 years out of actually getting into patients and then established in the market and generating any actual revenue and actual profit ????
I also assume Edwards, Medtronic, Abbott and multiple smaller others would have their own versions of adapt in their valves and would have ongoing money invested into developing them . a lot will depend on long term data from clinical trials and the other TAVR products have nearly 10 years of this data on file and Edwards are smashing the US the market , so what can this offer over and above ? what Edwards will come out with in the future .Have a look at this. Looks impressive with good experience. A long long long road to get this level

www.edwards.com/gb/devices/Heart-Valves/Transcatheter-Sapien-3

With China now blocking all USA medical devices the global market looks smaller
so back to your question in my opinion probably not at the moment I think its over valued